- Home
- BROS vs MDGL Comparison
BROS vs MDGL Comparison
Compare BROS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROS
- MDGL
- Stock Information
- Founded
- BROS 1992
- MDGL 2011
- Country
- BROS United States
- MDGL United States
- Employees
- BROS N/A
- MDGL N/A
- Industry
- BROS Restaurants
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- BROS Consumer Discretionary
- MDGL Health Care
- Exchange
- BROS Nasdaq
- MDGL Nasdaq
- Market Cap
- BROS 7.6B
- MDGL 7.1B
- IPO Year
- BROS 2021
- MDGL N/A
- Fundamental
- Price
- BROS $58.27
- MDGL $301.66
- Analyst Decision
- BROS Strong Buy
- MDGL Buy
- Analyst Count
- BROS 14
- MDGL 10
- Target Price
- BROS $78.86
- MDGL $354.75
- AVG Volume (30 Days)
- BROS 3.6M
- MDGL 317.2K
- Earning Date
- BROS 05-06-2025
- MDGL 05-06-2025
- Dividend Yield
- BROS N/A
- MDGL N/A
- EPS Growth
- BROS 1127.26
- MDGL N/A
- EPS
- BROS 0.34
- MDGL N/A
- Revenue
- BROS $1,281,015,000.00
- MDGL $180,133,000.00
- Revenue This Year
- BROS $26.07
- MDGL $228.41
- Revenue Next Year
- BROS $23.47
- MDGL $73.44
- P/E Ratio
- BROS $171.56
- MDGL N/A
- Revenue Growth
- BROS 32.64
- MDGL N/A
- 52 Week Low
- BROS $26.85
- MDGL $189.00
- 52 Week High
- BROS $86.88
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- BROS 45.31
- MDGL 40.18
- Support Level
- BROS $56.25
- MDGL $292.49
- Resistance Level
- BROS $59.94
- MDGL $330.64
- Average True Range (ATR)
- BROS 4.35
- MDGL 20.56
- MACD
- BROS 0.22
- MDGL -1.56
- Stochastic Oscillator
- BROS 67.02
- MDGL 22.48
About BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.